Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Founders Capital Management LLC

Key Points

• Founders Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 7.0%, owning 8,274 shares valued at approximately $4.34 million, marking it as the firm's 25th largest position.
• The stock currently has a consensus rating of "Moderate Buy" from analysts, with a target price range reflecting recent downgrades and adjustments, averaging around $817.67.
• Regeneron recently reported $12.89 EPS for the last quarter, significantly surpassing the estimated $8.43, with quarterly revenues of $3.68 billion also exceeding expectations.

Founders Capital Management LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,274 shares of the biopharmaceutical company's stock after purchasing an additional 538 shares during the quarter. Regeneron Pharmaceuticals makes up 0.7% of Founders Capital Management LLC's investment portfolio, making the stock its 25th largest position. Founders Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $4,344,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares in the last quarter. Nuveen LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $343,764,000. Pacer Advisors Inc. grew its position in Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after purchasing an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after purchasing an additional 303,785 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $127,215,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent analyst reports. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price for the company. in a report on Friday, August 1st. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday, August 11th. Citigroup restated a "buy" rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Jefferies Financial Group raised their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research report on Wednesday, August 27th. Finally, Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $591.99 on Monday. The stock's 50 day moving average price is $567.77 and its 200 day moving average price is $574.26. The firm has a market capitalization of $62.75 billion, a PE ratio of 14.92, a price-to-earnings-growth ratio of 1.98 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,154.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $11.56 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.